BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21939503)

  • 1. Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR.
    Wang D; Su L; Huang D; Zhang H; Shin DM; Chen ZG
    Mol Cancer; 2011 Sep; 10():116. PubMed ID: 21939503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells.
    Huang DH; Su L; Peng XH; Zhang H; Khuri FR; Shin DM; Chen ZG
    Nanotechnology; 2009 Jun; 20(22):225102. PubMed ID: 19433879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation.
    Muller S; Su L; Tighiouart M; Saba N; Zhang H; Shin DM; Chen Z
    Cancer; 2008 Jul; 113(1):97-107. PubMed ID: 18473353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage.
    Pannone G; Santoro A; Feola A; Bufo P; Papagerakis P; Lo Muzio L; Staibano S; Ionna F; Longo F; Franco R; Aquino G; Contaldo M; De Maria S; Serpico R; De Rosa A; Rubini C; Papagerakis S; Giovane A; Tombolini V; Giordano A; Caraglia M; Di Domenico M
    Curr Cancer Drug Targets; 2014; 14(2):115-27. PubMed ID: 24274398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
    Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
    Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RhoC mediates epidermal growth factor-stimulated migration and invasion in head and neck squamous cell carcinoma.
    Tumur Z; Katebzadeh S; Guerra C; Bhushan L; Alkam T; Henson BS
    Neoplasia; 2015 Jan; 17(1):141-51. PubMed ID: 25622907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
    Hoeben A; Martin D; Clement PM; Cools J; Gutkind JS
    Int J Cancer; 2013 Mar; 132(5):1042-50. PubMed ID: 22865653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion.
    Rao VH; Kandel A; Lynch D; Pena Z; Marwaha N; Deng C; Watson P; Hansen LA
    Oncogene; 2012 Jun; 31(23):2888-98. PubMed ID: 21986939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
    Zhang X; Zhang H; Tighiouart M; Lee JE; Shin HJ; Khuri FR; Yang CS; Chen Z'; Shin DM
    Int J Cancer; 2008 Sep; 123(5):1005-14. PubMed ID: 18546267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
    Boehm AL; Sen M; Seethala R; Gooding WE; Freilino M; Wong SM; Wang S; Johnson DE; Grandis JR
    Mol Pharmacol; 2008 Jun; 73(6):1632-42. PubMed ID: 18326051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.
    Haddad Y; Choi W; McConkey DJ
    Clin Cancer Res; 2009 Jan; 15(2):532-42. PubMed ID: 19147758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.
    Sobhakumari A; Schickling BM; Love-Homan L; Raeburn A; Fletcher EV; Case AJ; Domann FE; Miller FJ; Simons AL
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):736-45. PubMed ID: 23917044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.
    Fletcher EV; Love-Homan L; Sobhakumari A; Feddersen CR; Koch AT; Goel A; Simons AL
    Mol Cancer Res; 2013 Dec; 11(12):1574-84. PubMed ID: 24048704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
    Young NR; Liu J; Pierce C; Wei TF; Grushko T; Olopade OI; Liu W; Shen C; Seiwert TY; Cohen EE
    Mol Oncol; 2013 Jun; 7(3):359-68. PubMed ID: 23200321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
    Hah JH; Zhao M; Pickering CR; Frederick MJ; Andrews GA; Jasser SA; Fooshee DR; Milas ZL; Galer C; Sano D; William WN; Kim E; Heymach J; Byers LA; Papadimitrakopoulou V; Myers JN
    Head Neck; 2014 Nov; 36(11):1547-54. PubMed ID: 24123531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
    Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
    J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epidermal growth factor receptor gene amplification and E-cadherin expression in head and neck carcinomas].
    Rodrigo Tapia JP; Domínguez Iglesias F; Alvarez Marcos C; González Meana MV; García Pedrero J; Suárez Nieto C
    Acta Otorrinolaringol Esp; 2004 Dec; 55(10):482-7. PubMed ID: 15658558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.